托法替布治疗强直性脊柱炎的研究进展  

Progress of Tofacitinib in the Treatment of Ankylosing Spondylitis

作　　者：杨逸冰 李江涛[2] 

机构地区：[1]川北医学院临床医学院,四川 南充 [2]宜宾市第一人民医院风湿免疫科,四川 宜宾

出　　处：《临床医学进展》2024年第5期2221-2228,共8页Advances in Clinical Medicine

摘　　要：强直性脊柱炎是一种病因不明的慢性炎症性疾病。目前尚缺乏根治的方法,治疗上以非甾体抗炎药、改善病情抗风湿药为主,但疗效不一,部分患者病情仍无法有效控制。随着托法替布在临床的长期应用,其治疗强直性脊柱炎的疗效及安全性已得到了肯定,可能为临床用药提供新的选择。本文将结合最新的临床研究,针对托法替布治疗强直性脊柱炎的作用机制、有效性及安全性评价等方面进行综述,希望为临床用药提供新的选择。Ankylosing spondylitis is a chronic inflammatory disease of unknown etiology. At present, there is still a lack of radical treatment, and the treatment is mainly non-steroidal anti-inflammatory drugs and disease-modifying anti-rheumatic drugs, but the efficacy is different, and the condition of some patients is still not effectively controlled. With the long-term clinical application of tofacitinib, its efficacy and safety in the treatment of ankylosing spondylitis have been affirmed, which may provide a new choice for clinical use. This article will review the mechanism, efficacy and safety evaluation of tofacitinib in the treatment of ankylosing spondylitis in combination with the latest clinical research, hoping to provide new options for clinical use.

关 键 词：强直性脊柱炎 托法替布 JAK抑制剂 有效性 安全性 

分 类 号：R59[医药卫生—内科学]